Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 12/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 6/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.37 |
| ▸ | PRKCB | P05771 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1368936 | 0.85 | CDK2 (0.42) | CDK2CCNA2CCNA1NR1H2GSK3B | |
| SCHEMBL1837535 | 0.76 | NR1H2 (0.36) | CDK2CCNA2CCNA1NR1H2GSK3B | |
| SCHEMBL22095959 | 0.76 | C5AR1 (0.39) | CDK2CCNA2CCNA1NR1H2GSK3B | |
| SCHEMBL3326904 | 0.74 | PRKCB (0.65) | CDK2CCNA2CCNA1PAK4PRKCB | |
| SCHEMBL7947109 | 0.73 | NR1H2 (0.36) | CDK2CCNA2CCNA1NR1H2C5AR1 | |
| SCHEMBL26407436 | 0.72 | NR1H2 (0.35) | CDK2CCNA2CCNA1NR1H2C5AR1 | |
| SCHEMBL19195046 | 0.72 | NR1H2 (0.38) | CDK2CCNA2CCNA1NR1H2GSK3B | |
| SCHEMBL25947656 | 0.72 | CDK2 (0.59) | CDK2CCNA2CCNA1GSK3BCDK1 | |
| SCHEMBL17878698 | 0.71 | NR1H2 (0.37) | CDK2CCNA2CCNA1NR1H2C5AR1 | |
| SCHEMBL3327199 | 0.71 | PRKCB (0.53) | PAK4PRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518060-B2 | Substituted pyrrolo[3,4-c]pyrazoles as PKC kinase inhibitors | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150099743-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PFIZER INC. | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099743-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PRKCB, PRKCA, PRKCQ | CDK2 133/4885CCNA2 1729/4885CCNA1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.